Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...

综上所述，2024 ASH 年会展示的这些 BCMA 靶向疗法的临床试验结果令人振奋，为 MM 患者带来了新的希望。这些研究成果不仅进一步证实了 BCMA 靶向疗法在 MM 治疗中的有效性，还为不同阶段 MM ...

An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was instead diagnosed with multiple myeloma, according to a case report ...

Panelists discuss how recent FDA approvals for bispecific antibodies in oncology, particularly for hematologic malignancies like multiple myeloma and lymphomas, represent significant treatment ...

Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma: Paris Wednesday, February 26, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour and Welfare ...

Worship Walker County will hold its Women’s Breakfast on Friday, March 21 at 8:30 a.m. at Morning Pointe at Happy Valley. The ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal ...

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...

("Kangpu") today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China ...